Photo Credit: by wayhomestudio, freepik.com
While allergy season approaches, there is something different in the air – or at least, staying there longer. According to the American Lung Association, the pollen season is about three weeks longer now compared to 50 years ago. Furthermore, as a product of increased greenhouse gases and climate changes, they report a 20% increase in pollen production by plants and trees during this period as well. This has contributed to an earlier start to allergy season with even more severe symptoms. With Hay Fever, or Allergic Rhinitis, affecting up to 60 million people annually in the United States according to the CDC, the treatment options become more important than ever. With new emerging treatment options now available when standard therapy isn’t enough, there is much to discuss in the world of allergy management.
First-Line Treatment Still Matters: Modern Antihistamines
When the sneezing and sniffling sounds of allergy season approach, it’s important to know what treatment options are available. Current evidence recommends second-generation antihistamines as first-line treatments for allergic rhinitis and urticaria (hives). As they are better tolerated and less sedating, they are preferred over their first-generation counterparts. Second-generation antihistamine medications include cetirizine, levocetirizine, and loratadine, among many others.
Intranasal Corticosteroids: The Most Effective OTC Allergy Medication
The second-generation antihistamines are first-line options for allergic rhinitis, along with intranasal corticosteroids. These are not only considered first-line treatments, but some sources also cite them as the most effective treatment option for allergic rhinitis. Common intranasal corticosteroid options include beclomethasone, budesonide, and fluticasone. By working directly at the site of inflammation, they help to relieve the common symptoms of allergic rhinitis, including nasal congestion, runny nose, and sneezing. In fact, one study published in the American Journal of Rhinology & Allergy in 2017 found intranasal corticosteroids to be superior to oral antihistamines in relieving the symptoms of allergic rhinitis.
For The Symptoms That Won’t Quit: Intranasal Antihistamines
If intranasal corticosteroids and oral antihistamines aren’t doing the trick in relieving your symptoms of allergic rhinitis, another option in the allergy relief toolbox is intranasal antihistamines. They offer the advantage of delivering medication directly to the site of symptoms, like intranasal corticosteroids. However, they remain only an alternative due to their adverse effects (including bitter aftertaste, headache, nasal irritation, bloody nose, and sedation), their cost relative to oral counterparts, and their inferior effectiveness compared to intranasal corticosteroids. The two FDA-approved options for allergic rhinitis include Azelastine and Olopatadine. In fact, one study found that combination therapies, including intranasal antihistamine/intranasal corticosteroid and oral antihistamine/intranasal corticosteroid combination regimens, were superior to any single regimen alone for treating moderate to severe allergic rhinitis. Furthermore, the combination regimen of intranasal antihistamine and intranasal corticosteroid provided the greatest symptom relief in this study.
The New Frontier: Biologic Therapies for Severe Allergic Disease
There have been emerging treatment options for specific allergic conditions, notably chronic rhinosinusitis with nasal polyps and allergic asthma, with biologic medications. These biologic medications target antibodies and other signaling molecules involved in the allergic response pathway within our bodies. Currently, however, these biologic medications—while used to treat related allergic conditions—are FDA-approved only for the conditions listed above, not for allergic rhinitis alone. These include Dupilumab, which is approved for chronic rhinosinusitis with nasal polyps, moderate-to-severe atopic dermatitis, and moderate-to-severe asthma. Also, Omalizumab is indicated for moderate-to-severe asthma, chronic rhinosinusitis with nasal polyps, IgE-mediated food allergy, and chronic spontaneous urticaria in specific patient populations. Nonetheless, given these promising and related indications, there is hope that these emerging medications may one day be approved for allergic rhinitis in those who fail standard treatment regimens.
Longer Allergy Seasons Demand Smarter Treatment
Allergy season may be arriving earlier and lasting longer, but so too has our ability to manage it effectively. What was once approached with a single over-the-counter medication and a wait-it-out mentality has evolved into a more structured, evidence-based strategy. For many patients, consistent use of second-generation antihistamines and intranasal corticosteroids remains the cornerstone of therapy—and when started early and used properly, these treatments can significantly reduce symptom burden. For those with persistent or moderate-to-severe symptoms, step-up options such as intranasal antihistamines or combination regimens offer meaningful additional relief. As always, individuals should consult their physician, pharmacist, or other qualified healthcare professional before starting any new medication or changing their current treatment regimen.
Importantly, the emergence of biologic therapies for related allergic conditions signals a broader shift in how we understand and treat allergic disease. Rather than simply blocking histamine, newer treatments increasingly target the underlying immune pathways that drive inflammation. While biologics are not currently FDA-approved for allergic rhinitis alone, their success in asthma, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria reflects a promising future direction for patients whose symptoms remain difficult to control.
As environmental changes continue to intensify pollen seasons, patients may need to rethink how they approach allergy management. Allergy care today is no longer just reactive—it is preventive, personalized, and increasingly precise. With the right strategy, even a longer and more intense allergy season does not have to mean months of uncontrolled symptoms.
Related Articles:
https://www.bbc.com/future/article/20260313-hay-fever-the-new-wave-of-effective-cures-for-seasonal-allergies
https://theconversation.com/hay-fever-season-is-coming-heres-how-to-get-ahead-of-symptoms-275478
https://www.rte.ie/brainstorm/2026/0327/1564000-hay-fever-season-march-september-symptoms-allergies-spring-health/
https://www.daytondailynews.com/local/tips-to-keep-springtime-allergies-under-control-in-ohio/QARQV2JKBRADTJ63KTGK6DY5PU-2/
###